7-(2,4-dichlorophenyl)-4-[(2S,4R)-4-methoxy-2-(methoxymethyl)pyrrolidin-1-yl]-2,6-dimethylpyrrolo[1,2-b]pyridazine | 793673-45-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 7-(2,4-dichlorophenyl)-4-[(2S,4R)-4-methoxy-2-(methoxymethyl)pyrrolidin-1-yl]-2,6-dimethylpyrrolo[1,2-b]pyridazine
• CAS: 793673-45-7
• 化学式: C₂₂H₂₅Cl₂N₃O₂
• 分子量: 434.365
• InChiKey: NVNAZBJHDRXNSV-DLBZAZTESA-N

物化性质

• 密度：
  1.32±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  39
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Pyrrolo[1,2-b]pyridazine compounds
  申请人：Pfizer Inc

  公开号：US20040242587A1

  公开（公告）日：2004-12-02

  This invention relates to substituted pyrrolo[1,2-b]pyridazine compounds of Formula I, 1 a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF 1 receptors, including human CRF 1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.

  本发明涉及式I的取代吡咯并[1,2-b]吡啶嗪化合物，其立体异构体，其药学上可接受的盐，其前药或其药学上可接受的前药盐。该化合物与CRF1受体相互作用，包括人类CRF1受体。本发明还涉及使用本发明的化合物治疗疾病或病症的方法，该治疗可以通过拮抗CRF受体来实现或促进，例如中枢神经系统疾病或疾病，特别是焦虑相关疾病，如焦虑症，以及情绪障碍，如重度抑郁症。
• PYRROLO[1,2-B]PYRIDAZINE COMPOUNDS AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1622911A2

  公开（公告）日：2006-02-08
• [EN] PYRROLO[1,2-B]PYRIDAZINE COMPOUNDS<br/>[FR] COMPOSES PYRROLO[1,2-B]PYRIDAZINIQUES
  申请人：UPJOHN CO

  公开号：WO2004099213A2

  公开（公告）日：2004-11-18

  This invention relates to substituted pyrrolo[1,2-b]pyridazine compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF1, receptors, including human CRF1, receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.